Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients.

ABSTRACT:

Background

High-dose Interferon (HDI) therapy produces a clinical response and achieves relapse-free survival in 20-33% of patients with operable high risk or metastatic melanoma. However, patients may develop significant side effects frequently necessitating dose reduction or discontinuation of therapy. We recently showed that peripheral blood lymphocytes (PBL) from some melanoma patients have impaired interferon (IFN) signaling which could be restored with high concentrations of IFN. This exploratory study evaluated IFN signaling in PBL of melanoma patients to assess whether the restoration of PBL IFN signaling may predict a beneficial effect for HDI in melanoma patients.

Methods

PBL from 14 melanoma patients harvested on Day 0 and Day 29 of neoadjuvant HDI induction thera

SUBMITTER: Simons DL 

PROVIDER: S-EPMC3114759 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature